IPP-201101
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for IPP-201101, covering 2019-04-11 to 2019-04-11. Get the full timeline:
Most recent: Clinical Trial Update: A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus [Phase 3]